标题
Strategies and challenges for the next generation of antibody–drug conjugates
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 16, Issue 5, Pages 315-337
出版商
Springer Nature
发表日期
2017-03-17
DOI
10.1038/nrd.2016.268
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Characterization of cetuximab Fc/2 dimers by off-line CZE-MS
- (2016) Yannis-Nicolas François et al. ANALYTICA CHIMICA ACTA
- Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma
- (2016) Cong Wei et al. ANALYTICAL CHEMISTRY
- From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
- (2016) Julia Mantaj et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- One-Step Conjugation Method for Site-Specific Antibody–Drug Conjugates through Reactive Cysteine-Engineered Antibodies
- (2016) Daisuke Shinmi et al. BIOCONJUGATE CHEMISTRY
- Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates
- (2016) Sujiet Puthenveetil et al. BIOCONJUGATE CHEMISTRY
- Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
- (2016) Takashi Nakada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry
- (2016) Filip S. Ekholm et al. ChemMedChem
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Antibody-drug conjugates for non-oncological indications
- (2016) Renhe Liu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates
- (2016) Alain Beck et al. Expert Review of Proteomics
- Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I − Optimization of separation conditions
- (2016) Morgan Sarrut et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization
- (2016) Guillaume Terral et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species
- (2016) Mélissa Excoffier et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection
- (2016) Dwight Stoll et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. II- Identification of sub-units for the characterization of even and odd load drug species
- (2016) Morgan Sarrut et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products
- (2016) Rabah Gahoual et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase
- (2016) Marta Rodriguez-Aller et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Rethinking the INN system for therapeutic antibodies
- (2016) Jérémy Pottier et al. mAbs
- Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice
- (2016) Chenguang Zhou et al. mAbs
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Resistance to Antibody–Drug Conjugates
- (2016) Frank Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
- (2016) M. L. Miller et al. MOLECULAR CANCER THERAPEUTICS
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
- (2016) M. J. Flynn et al. MOLECULAR CANCER THERAPEUTICS
- 2015 FDA drug approvals
- (2016) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- RP-HPLC DAR Characterization of Site-Specific Antibody Drug Conjugates Produced in a Cell-Free Expression System
- (2016) Yiren Xu et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- 2-(Maleimidomethyl)-1,3-Dioxanes (MD): a Serum-Stable Self-hydrolysable Hydrophilic Alternative to Classical Maleimide Conjugation
- (2016) Igor Dovgan et al. Scientific Reports
- Conformational Difference in Human IgG2 Disulfide Isoforms Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry
- (2015) Aming Zhang et al. BIOCHEMISTRY
- Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates
- (2015) Remon van Geel et al. BIOCONJUGATE CHEMISTRY
- Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
- (2015) Magdalena Dorywalska et al. BIOCONJUGATE CHEMISTRY
- Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins
- (2015) Hannes Merten et al. BIOCONJUGATE CHEMISTRY
- Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody–Drug Conjugates Using Click Cycloaddition Chemistry
- (2015) Michael P. VanBrunt et al. BIOCONJUGATE CHEMISTRY
- Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody
- (2015) Pamela Thompson et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues
- (2015) Xiuling Li et al. BIOCONJUGATE CHEMISTRY
- Covalent Chemical Ligation Strategy for Mono- and Polyclonal Immunoglobulins at Their Nucleotide Binding Sites
- (2015) Diana Lac et al. BIOCONJUGATE CHEMISTRY
- CBTF: New Amine-to-Thiol Coupling Reagent for Preparation of Antibody Conjugates with Increased Plasma Stability
- (2015) Sergii Kolodych et al. BIOCONJUGATE CHEMISTRY
- Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases
- (2015) Pradman K. Qasba BIOCONJUGATE CHEMISTRY
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
- (2015) Gregory S. Hamilton BIOLOGICALS
- The cryptophycins as potent payloads for antibody drug conjugates
- (2015) Vishal A. Verma et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
- (2015) Taofeek Kunle Owonikoko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract 397: Rebastinib potently inhibits function of perivascular TIE2 expressing macrophagesin vitroandin vivo
- (2015) Allison Harney et al. CANCER RESEARCH
- Abstract DDT02-04: SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)
- (2015) Dana A. Kennedy et al. CANCER RESEARCH
- A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
- (2015) A. V. Yurkovetskiy et al. CANCER RESEARCH
- Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
- (2015) B. Shor et al. CLINICAL CANCER RESEARCH
- A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
- (2015) S.-F. Yu et al. CLINICAL CANCER RESEARCH
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
- (2015) M. Damelin et al. CLINICAL CANCER RESEARCH
- Antibody-targeted drugs and drug resistance—Challenges and solutions
- (2015) LeeRon Shefet-Carasso et al. DRUG RESISTANCE UPDATES
- Emerging formats for next-generation antibody drug conjugates
- (2015) Mahendra P Deonarain et al. Expert Opinion on Drug Discovery
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides
- (2015) R. James Christie et al. JOURNAL OF CONTROLLED RELEASE
- Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies
- (2015) Alain Beck et al. JOURNAL OF MASS SPECTROMETRY
- Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody–Drug Conjugates
- (2015) Brian Wiggins et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- An Immunosuppressive Antibody–Drug Conjugate
- (2015) Rongsheng E. Wang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection
- (2015) Robert E. Birdsall et al. mAbs
- The INNs and outs of antibody nonproprietary names
- (2015) Tim D. Jones et al. mAbs
- IMGN853, a Folate Receptor- (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors
- (2015) O. Ab et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
- (2015) R. Gebleux et al. MOLECULAR CANCER THERAPEUTICS
- Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies
- (2015) C. Rouleau et al. MOLECULAR CANCER THERAPEUTICS
- Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
- (2015) A. Visintin et al. MOLECULAR CANCER THERAPEUTICS
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
- (2015) D. S. Pereira et al. MOLECULAR CANCER THERAPEUTICS
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
- (2015) M. M. C. van der Lee et al. MOLECULAR CANCER THERAPEUTICS
- High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates
- (2015) B. E. C. G. de Goeij et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
- (2015) Boris Shor et al. MOLECULAR IMMUNOLOGY
- Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models
- (2015) F. Lhospice et al. MOLECULAR PHARMACEUTICS
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
- (2015) Christopher R. Behrens et al. MOLECULAR PHARMACEUTICS
- Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation
- (2015) E. Erica Hong et al. MOLECULAR PHARMACEUTICS
- In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios
- (2015) Penny Bryant et al. MOLECULAR PHARMACEUTICS
- Sensitive ELISA Method for the Measurement of Catabolites of Antibody–Drug Conjugates (ADCs) in Target Cancer Cells
- (2015) Paulin L. Salomon et al. MOLECULAR PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers
- (2015) Bryan C. Murray et al. NATURAL PRODUCT REPORTS
- TP53 loss creates therapeutic vulnerability in colorectal cancer
- (2015) Yunhua Liu et al. NATURE
- Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
- (2015) Sophie M. Lehar et al. NATURE
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading
- (2015) Pavel Strop et al. NATURE BIOTECHNOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving Strategies for Target Selection for Antibody-Drug Conjugates
- (2015) Marc Damelin et al. PHARMACEUTICAL RESEARCH
- Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate
- (2015) Julien Marcoux et al. PROTEIN SCIENCE
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
- (2015) Laura R. Saunders et al. Science Translational Medicine
- Synthesis of a C2-aryl-pyrrolo[2,1-c][1,4]benzodiazepine monomer enabling the convergent construction of symmetrical and non-symmetrical dimeric analogs
- (2015) Robert V. Kolakowski et al. TETRAHEDRON LETTERS
- A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
- (2015) Antoine Maruani et al. Nature Communications
- A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
- (2015) S Y Kim et al. Blood Cancer Journal
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency
- (2015) Roger R. Beerli et al. PLoS One
- Innovative Native MS Methodologies for Antibody Drug Conjugate Characterization: High Resolution Native MS and IM-MS for Average DAR and DAR Distribution Assessment
- (2014) François Debaene et al. ANALYTICAL CHEMISTRY
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Preparation of Well-Defined Antibody-Drug Conjugates through Glycan Remodeling and Strain-Promoted Azide-Alkyne Cycloadditions
- (2014) Xiuru Li et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers
- (2014) James T. Patterson et al. BIOCONJUGATE CHEMISTRY
- Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy
- (2014) L. Nathan Tumey et al. BIOCONJUGATE CHEMISTRY
- Long-Term Stabilization of Maleimide–Thiol Conjugates
- (2014) Shaun D. Fontaine et al. BIOCONJUGATE CHEMISTRY
- Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System
- (2014) Erik S. Zimmerman et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Antibody–Drug Conjugation through Glycoengineering
- (2014) Qun Zhou et al. BIOCONJUGATE CHEMISTRY
- Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes
- (2014) Penelope M. Drake et al. BIOCONJUGATE CHEMISTRY
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Exploring the effects of linker composition on site-specifically modified antibody–drug conjugates
- (2014) Aaron E. Albers et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- A Chemically Defined Trifunctional Antibody-Cytokine-Drug Conjugate with Potent Antitumor Activity
- (2014) T. List et al. MOLECULAR CANCER THERAPEUTICS
- Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
- (2014) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Methods to Make Homogenous Antibody Drug Conjugates
- (2014) Toni Kline et al. PHARMACEUTICAL RESEARCH
- In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
- (2014) Dowdy Jackson et al. PLoS One
- A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
- (2014) A. E. Prota et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/ -ketoglutarate-dependent dioxygenase
- (2014) A. S. Eustaquio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A general approach to site-specific antibody drug conjugates
- (2014) Feng Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
- (2014) P. Muller et al. Cancer Immunology Research
- Time Resolved Native Ion-Mobility Mass Spectrometry to Monitor Dynamics of IgG4 Fab Arm Exchange and “Bispecific” Monoclonal Antibody Formation
- (2013) François Debaene et al. ANALYTICAL CHEMISTRY
- Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation
- (2013) Nicole M. Okeley et al. BIOCONJUGATE CHEMISTRY
- A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
- (2013) Scott C. Jeffrey et al. BIOCONJUGATE CHEMISTRY
- Why is it so difficult to use gemtuzumab ozogamicin?
- (2013) BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Antibody–drug conjugates: current status and future directions
- (2013) Heidi L. Perez et al. DRUG DISCOVERY TODAY
- Approval of the first biosimilar antibodies in Europe
- (2013) Alain Beck et al. mAbs
- 8thAnnual European Antibody Congress 2012
- (2013) Alain Beck et al. mAbs
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Antibody-drug conjugates
- (2013) Alain Beck et al. mAbs
- Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion
- (2013) Elsa Wagner-Rousset et al. mAbs
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
- (2013) Omid Vafa et al. METHODS
- Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers
- (2013) S. V. Govindan et al. MOLECULAR CANCER THERAPEUTICS
- The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
- (2013) Hans-Peter Gerber et al. NATURAL PRODUCT REPORTS
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- PK assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine
- (2013) Randall Dere et al. Bioanalysis
- Characterization of Therapeutic Antibodies and Related Products
- (2012) Alain Beck et al. ANALYTICAL CHEMISTRY
- Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format
- (2012) Kathrin Zuberbühler et al. CHEMICAL COMMUNICATIONS
- Marketing approval of mogamulizumab
- (2012) Alain Beck et al. mAbs
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Brentuximab vedotin
- (2012) Anas Younes et al. NATURE REVIEWS DRUG DISCOVERY
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- Design and Application of Antibody Cysteine Variants
- (2010) Vladimir Voynov et al. BIOCONJUGATE CHEMISTRY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- (2009) Hans K. Erickson et al. BIOCONJUGATE CHEMISTRY
- P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
- (2009) Ruoping Tang et al. BMC CANCER
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
- (2009) Aran F Labrijn et al. NATURE BIOTECHNOLOGY
- Editorial [Hot Topic: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic(Guest Editor: Alain Beck)]
- (2008) A. Beck et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
- (2008) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now